Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
Komal Jhaveri, MD, FACP
Kevin Kalinsky MD, MS
From Pathway to Patient: Clinical Advances in PI3K-Directed Therapy for HR+/HER2- mBC
Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
Case in Point: Applying PI3K Combinations in Early Recurrent HR+/HER2- mBC
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Insights and Updates: New Data on Next-Generation Retinal Treatments
Durga Borkar, MD, MMCi
Veeral Sheth, MD, MBA, FASRS, FACS
Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
Safety First: Navigating CELMoD-Associated Toxicities
Joshua Richter, MD
Noopur Raje, MD
Real-World Ready: Practical Tips for Community Oncologists
Sagar Lonial, MD, FACP
Why CELMoDs Matter in Myeloma
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
Maria Fleseriu, MD, FACE
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Understanding Endocrine Resistance in HR+/HER2- mBC
PI3K Pathway Inhibitors: Safety and Tolerability Profiles
Molecular Magic: Decoding the Unique Mechanism of CELMoDs
Data Dive: Clinical Evidence Behind CELMoDs
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.